|
|
CerviLenz® is an innovative tool that measures vaginal cervical length objectively to help identify women at risk for preterm labor during pregnancy. In the US, nearly 13% of babies are born preterm (before 37 completed weeks gestation). Prematurity is a leading cause of newborn mortality and morbidity. CerviLenz is FDA cleared and will be commercially available later this year.
Funders:
Jumpstart, North Coast Angel Fund, Arboretum Ventures, Chrysalis Ventures
|
|
|